CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 54 enrolled
Drug / intervention
GSK3640254 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04630002
NCT04630002Phase 1Completed
CompareCT.gov

Open-Label, Single-Sequence Study to Evaluate the Effects of Darunavir/Ritonavir and/or Etravirine on the Pharmacokinetics of GSK3640254 and the Effects of GSK3640254 on the Pharmacokinetics of Darunavir/Ritonavir and/or Etravirine in Heathy Adults

ViiV Healthcare·interventional·Posted Nov 16, 2020·Updated Aug 29, 2024

In Brief

A Phase 1 clinical trial evaluating GSK3640254, Darunavir/Ritonavir (DRV/RTV), and 1 other intervention for HIV Infections. Completed, enrolled 54 participants across 1 site.

Detailed Summary

This is an open-label, single-sequence, multiple-dose, 3 cohort study to investigate the effects of DRV/RTV and/or ETR on the pharmacokinetics (PK) of GSK3640254 and the effects of GSK3640254 on the PK of DRV/RTV and/or ETR. This study will aid in understanding these interactions and resulting changes in exposure (if any) when given in combination with GSK3640254.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedNov 16, 2020
Enrollment StartOct 28, 2020
Primary CompletionOct 2, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.6 years ago

Interventions

GSK3640254drug

GSK3640254 will be available as oral tablets.

Darunavir/Ritonavir (DRV/RTV)drug

DRV/RTV will be available as oral tablets.

Etravirine (ETR)drug

ETR will be available as oral tablets.